{"id":11444,"date":"2023-11-17T22:58:00","date_gmt":"2023-11-17T14:58:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11444"},"modified":"2024-11-05T23:01:33","modified_gmt":"2024-11-05T15:01:33","slug":"yipinhong-pharmacys-ar882-shows-promise-in-gout-treatment-in-phase-ii-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11444","title":{"rendered":"Yipinhong Pharmacy’s AR882 Shows Promise in Gout Treatment in Phase II Study"},"content":{"rendered":"\n

China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723<\/a>) has announced positive data from a Phase II clinical study for its pipeline candidate drug AR882, co-developed with Arthrosi Therapeutics Inc., for the treatment of gout. The randomized, placebo-controlled global study involved 42 patients, and after 6 weeks of treatment, results indicated that AR882 significantly reduced serum uric acid (sUA) levels in gout sufferers, alleviated disease symptoms, and dissolved the volume of urate crystals. The drug demonstrated better efficacy and higher safety compared to existing therapies for treating gout patients.<\/p>\n\n\n\n

AR882’s Efficacy and Safety Profile in Gout Management<\/strong><\/p>\n\n\n\n

AR882 is a highly effective and selective uric acid transporter (URAT1) inhibitor that promotes the normalization of urine urate excretion and reduces sUA levels. Unlike other anti-gout drugs such as benzbromarone, AR882 can bind to the uric acid transporter for an extended period, prolonging inhibition. Clinical results showed that its efficacy lasted up to 24 hours. Moreover, its ability to block the reabsorption of uric acid around the clock does not increase kidney load, indicating no nephrotoxicity.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced positive data from a Phase II…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,1126,370],"class_list":["post-11444","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-she-300723","tag-yipinhong-pharmacy"],"yoast_head":"\nYipinhong Pharmacy's AR882 Shows Promise in Gout Treatment in Phase II Study - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced positive data from a Phase II clinical study for its pipeline candidate drug AR882, co-developed with Arthrosi Therapeutics Inc., for the treatment of gout. The randomized, placebo-controlled global study involved 42 patients, and after 6 weeks of treatment, results indicated that AR882 significantly reduced serum uric acid (sUA) levels in gout sufferers, alleviated disease symptoms, and dissolved the volume of urate crystals. The drug demonstrated better efficacy and higher safety compared to existing therapies for treating gout patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11444\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yipinhong Pharmacy's AR882 Shows Promise in Gout Treatment in Phase II Study\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11444\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-17T14:58:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-05T15:01:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11444#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11444\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Yipinhong Pharmacy’s AR882 Shows Promise in Gout Treatment in Phase II Study\",\"datePublished\":\"2023-11-17T14:58:00+00:00\",\"dateModified\":\"2024-11-05T15:01:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11444\"},\"wordCount\":185,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"SHE: 300723\",\"Yipinhong Pharmacy\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11444#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11444\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11444\",\"name\":\"Yipinhong Pharmacy's AR882 Shows Promise in Gout Treatment in Phase II Study - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-17T14:58:00+00:00\",\"dateModified\":\"2024-11-05T15:01:33+00:00\",\"description\":\"China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced positive data from a Phase II clinical study for its pipeline candidate drug AR882, co-developed with Arthrosi Therapeutics Inc., for the treatment of gout. The randomized, placebo-controlled global study involved 42 patients, and after 6 weeks of treatment, results indicated that AR882 significantly reduced serum uric acid (sUA) levels in gout sufferers, alleviated disease symptoms, and dissolved the volume of urate crystals. The drug demonstrated better efficacy and higher safety compared to existing therapies for treating gout patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11444#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11444\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11444#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yipinhong Pharmacy’s AR882 Shows Promise in Gout Treatment in Phase II Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Yipinhong Pharmacy's AR882 Shows Promise in Gout Treatment in Phase II Study - Insight, China's Pharmaceutical Industry","description":"China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced positive data from a Phase II clinical study for its pipeline candidate drug AR882, co-developed with Arthrosi Therapeutics Inc., for the treatment of gout. The randomized, placebo-controlled global study involved 42 patients, and after 6 weeks of treatment, results indicated that AR882 significantly reduced serum uric acid (sUA) levels in gout sufferers, alleviated disease symptoms, and dissolved the volume of urate crystals. The drug demonstrated better efficacy and higher safety compared to existing therapies for treating gout patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11444","og_locale":"en_US","og_type":"article","og_title":"Yipinhong Pharmacy's AR882 Shows Promise in Gout Treatment in Phase II Study","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11444","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-17T14:58:00+00:00","article_modified_time":"2024-11-05T15:01:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11444#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11444"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Yipinhong Pharmacy’s AR882 Shows Promise in Gout Treatment in Phase II Study","datePublished":"2023-11-17T14:58:00+00:00","dateModified":"2024-11-05T15:01:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11444"},"wordCount":185,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","SHE: 300723","Yipinhong Pharmacy"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11444#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11444","url":"https:\/\/flcube.com\/?p=11444","name":"Yipinhong Pharmacy's AR882 Shows Promise in Gout Treatment in Phase II Study - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-17T14:58:00+00:00","dateModified":"2024-11-05T15:01:33+00:00","description":"China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced positive data from a Phase II clinical study for its pipeline candidate drug AR882, co-developed with Arthrosi Therapeutics Inc., for the treatment of gout. The randomized, placebo-controlled global study involved 42 patients, and after 6 weeks of treatment, results indicated that AR882 significantly reduced serum uric acid (sUA) levels in gout sufferers, alleviated disease symptoms, and dissolved the volume of urate crystals. The drug demonstrated better efficacy and higher safety compared to existing therapies for treating gout patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11444#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11444"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11444#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Yipinhong Pharmacy’s AR882 Shows Promise in Gout Treatment in Phase II Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11444"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11444\/revisions"}],"predecessor-version":[{"id":11445,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11444\/revisions\/11445"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}